Modified polynucleotides for the production of proteins

Patent metadata

Field	Value
Publication number	US-9827332-B2
Application number	US-201514940512-A
Country	US
Kind code	B2
Filing date	Nov 13, 2015
Priority date	Apr 2, 2012
Publication date	Nov 28, 2017
Grant date	Nov 28, 2017

Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

First claim

We claim:

1. An isolated mRNA comprising;
(a) a first region of linked nucleosides, said first region having at least 80% identity to SEQ ID NO: 18020 encoding a polypeptide of interest, said polypeptide of interest having the sequence of SEQ ID NO: 9254;
(b) a first flanking region located at the 5′ terminus of said first region comprising;
(i) a sequence of linked nucleosides having the sequence of the native 5′ UTR of the nucleic acid that encodes SEQ ID NO: 9254, or having the sequence of SEQ ID NOs: 1-4; and
(ii) at least one 5′ terminal cap;

(c) a second flanking region located at the 3′ terminus of said first region comprising;
(i′) a sequence of linked nucleosides having the sequence of the native 3′ UTR of the nucleic acid that encodes SEQ ID NO: 9254, or having the sequence of SEQ ID NOs: 5-21; and
(ii′) a 3′ tailing sequence of linked nucleosides.

2. The isolated mRNA of claim 1 , wherein the first region of linked nucleosides comprises at least an open reading frame of a nucleic acid sequence having the sequence of SEQ ID NO: 18020.

3. The isolated mRNA of claim 1 , wherein the 3′ tailing sequence of linked nucleosides is selected from the group consisting of a poly-A tail of approximately 160 nucleotides and a polyA-G quartet.

4. The isolated mRNA of claim 1 which is purified.

5. The isolated mRNA of claim 1 , wherein the at least one 5′ terminal cap is selected from the group consisting of Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2′fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

6. The isolated mRNA of claim 1 , wherein at least one of said linked nucleosides comprises at least one modification as compared to the chemical structure of an A, G, U or C ribonucleotide.

7. The isolated mRNA of claim 6 , wherein at least one said modification is located in a nucleoside base and/or sugar portion.

8. The isolated mRNA of claim 1 , wherein said first region comprises n number of linked nucleosides having Formula (Ia):

or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein
U is O, S, N(R U ) nu , or C(R U ) nu , wherein nu is an integer from 0 to 2 and each R U is, independently, H, halo, or optionally substituted alkyl;
is a single or double bond;
is a single bond or absent;
each of R 1′ , R 2′ , R 1″ , R 2″ , R 3 , R 4 , and R 5 is, independently, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, or absent; wherein the combination of R 3 with one or more of R 1′ , R 1″ , R 2′ , R 2″ , or R 5 can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl; wherein the combination of R 5 with one or more of R 1′ , R 1″ , R 2′ , or R 2″ can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl; and wherein the combination of R 4 and one or more of R 1′ , R 1″ , R 2′ , R 2″ , R 3 , or R 5 can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl;
each of Y 1 , Y 2 , and y 3 , is, independently, O, S, —NR N1 —, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent;
each Y 4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;
each Y 5 is, independently, O, S, optionally substituted alkylene, or optionally substituted heteroalkylene;

n is an integer from 1 to 100,000; and
B is a nucleobase, wherein the combination of B and R 1 ′, the combination of B and R 2′ , the combination of B and R 1″ , or the combination of B and R 2″ can, taken together with the carbons to which they are attached, optionally form a bicyclic group or wherein the combination of B, R 1″ , and R 3 or the combination of B, R 2″ , and R 3 can optionally form a tricyclic or tetracyclic group.

9. The isolated mRNA of claim 8 , wherein B is not pseudouridine (ψ) or 5-methyl-cytidine (m 5 C).

10. The isolated mRNA of claim 8 , wherein
U is O or C(R U ) nu , wherein nu is an integer from 1 to 2 and each R U is, independently, H, halo, or optionally substituted alkyl;
each of R 1 , R 1′ , R 1″ , R 2 , R 2′ , and R 2″ , if present, is, independently, H, halo, hydroxy, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, or optionally substituted aminoalkyl;
each of R 3 and R 4 is, independently, H, halo, hydroxy, optionally substituted alkyl, or optionally substituted alkoxyalkoxy;
each of Y 1 , Y 2 , and Y 3 , is, independently, O, S, —NR N1 —, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;
each Y 4 is, independently, H, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, or optionally substituted amino;
each Y 5 is, independently, O or optionally substituted alkylene; and
n is an integer from 10 to 10,000.

11. The isolated mRNA of claim 10 , wherein each of R 1 , R 1′ , and R 1″ , if present, is H.

12. The isolated mRNA of claim 11 , wherein each of R 2 , R 2′ , and R 2″ , if present, is, independently, H, halo, hydroxy, optionally substituted alkoxy, or optionally substituted alkoxyalkoxy.

13. The isolated mRNA of claim 10 , wherein each of R 2 , R 2′ , and R 2″ , if present, is H.

14. The isolated mRNA of claim 13 , wherein each of R 1 , R 1′ , and R 1″ , if present, is, independently, H, halo, hydroxy, optionally substituted alkoxy, or optionally substituted alkoxyalkoxy.

15. The isolated mRNA of claim 8 , wherein said first region comprises n number of linked nucleotides having Formula (IIa):

or a pharmaceutically acceptable salt or stereoisomer thereof.

16. The isolated mRNA of claim 8 , wherein said first region comprises n number of linked nucleosides having Formula (IIk):

or a pharmaceutically acceptabl

Assignees

• Moderna Therapeutics Inc
• Modernatx Inc

Inventors

• Bancel Stephane
• Chakraborty Tirtha
• De Fougerolles Antonin
• Elbashir Sayda M
• Ellsworth Jeff Lynn
• Ejebe Kenechi
• Guild Justin
• John Matthias
• Hatala Paul
• Roy Atanu
• Schrum Jason P
• Whoriskey Susan
• Wood Kristy M

Classifications

• C07K14/56

  IFN-alpha · CPC title

• A61K9/5153

  Polyesters, e.g. poly(lactide-co-glycolide) · CPC title

• C12N15/85

  for animal cells · CPC title

• A61K38/17

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title